Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Capricor Therapeutics, Inc. - Common Stock (NQ:CAPR)

10.02 +0.32 (+3.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Capricor Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
FDA Skips Advisory Committee For Capricor's Duchenne Cell Therapy
Capricor's DMD therapy Deramiocel is under FDA Priority Review with no major issues flagged; PDUFA date set for August 31, 2025. 
Via Benzinga
Capricor Therapeutics Says FDA May Not Hold Advisory Committee Meeting For DMD Therapy Approval: Stock Soars But Analyst Issues Warning
The FDA has indicated that an advisory committee meeting is not required at this time, the company said, while adding that its application for Deramiocel approval remains under priority review. 
Via Stocktwits
Why Is Capricor Therapeutics Stock Trading Lower On Monday?
Capricor stock drops as FDA cancels advisory meeting on Duchenne therapy; leadership changes and regulatory tensions fuel uncertainty. 
Via Benzinga
Capricor Reports 4-Year Data For Deramiocel, Shows Sustained Benefit In Duchenne Patients
Capricor shares four-year data showing Deramiocel slowed DMD progression and preserved function, with maintained safety in long-term use. 
Via Benzinga
Top movers analysis one hour before the close of the markets on 2025-06-20: top gainers and losers in today's session.
Stay up-to-date with the latest market trends one hour before the close of the markets on Friday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
A Look Ahead: Capricor Therapeutics's Earnings Forecast
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Capricor Stock Slumps 16% On Report Of Key FDA Executive’s Removal, But Retail’s Hopeful About New 4-Year Deramiocel Data
Capricor on Friday announced positive four-year safety and efficacy results from its ongoing mid-stage study of its cell therapy Deramiocel, which failed to cheer investors. 
Via Stocktwits
Gapping stocks in Friday's session
The session on Friday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Beyond The Numbers: 7 Analysts Discuss Capricor Therapeutics Stock
Via Benzinga
Why Cheetah Mobile Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
Via Benzinga
FDA Completes Inspection of Capricor Therapeutics Manufacturing Facility For Deramiocel Approval: Retail Sees ‘Unimaginable Potential’
Capricor expressed confidence that the facility will meet the necessary requirements to support product licensure and commercial launch, pending approval. 
Via Stocktwits
Forecasting The Future: 5 Analyst Projections For Capricor Therapeutics
Via Benzinga
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation
FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns. 
Via Benzinga
Earnings Scheduled For May 13, 2025
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Capricor Therapeutics Stock Tumbles After FDA Confirms Intent To Hold Advisory Committee Meet For Deramiocel Approval: But Retail’s Optimistic
The U.S. FDA stated that its review committee has identified no significant deficiencies and is on track to make a decision on the application by its deadline of the end of August. 
Via Stocktwits
Topics Economy Government
uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Capricor Therapeutics’ CAP-1002: Regulatory Progress, Clinical Outcomes & Investment Outlook
If CAP-1002 (Deramiocel) is approved on schedule, deramiocel would become the first therapy indicated specifically for DMD-associated cardiomyopathy, addressing a critical unmet need. The StealthX(tm)... 
Via Talk Markets
Topics Stocks / Equities
FDA Advisory Committee Shakeup and Implications for Capricor Therapeutics
Don't be scared off up by the recent Trump FDA overhaul. The changes are very positive for Capricor Therapeutics moving forward (2025–2028). 
Via Talk Markets
Topics Government Stocks / Equities
Robinhood, Couchbase And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling more than 250 points on Monday. 
Via Benzinga
Topics Stocks
Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Capricor Therapeutics Stock Surges After Q4 Results Beat Estimates: Retail Gets More Bullish
The company said its available cash, cash equivalents, and marketable securities will be sufficient to cover the expenses and capital requirements into 2027. 
Via Stocktwits
Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday
Via Benzinga
A Glimpse Into The Expert Outlook On Capricor Therapeutics Through 4 Analysts
Via Benzinga
Earnings Scheduled For March 19, 2025
Via Benzinga
Capricor Therapeutics’ Retail Chatter Explodes On Stocktwits After FDA Grants Priority Review For DMD Therapy
The health agency has accepted Capricor's Biologics License Application for full approval of deramiocel as a treatment for Duchenne muscular dystrophy cardiomyopathy. 
Via Stocktwits
Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition
FDA grants Priority Review to Capricor's deramiocel for Duchenne cardiomyopathy, setting an August 2025 decision date with no identified review issues. 
Via Benzinga
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.